PT-141

PT-141 (Bremelanotide) is a melanocortin receptor agonist investigated primarily for its effects on central arousal pathways independent of nitric-oxide–mediated vascular mechanisms. Unlike agents that act peripherally, PT-141 engages the central melanocortin system to modulate neuroendocrine signaling related to desire, reward processing, and autonomic outflow. Research applications include the study of hypothalamic signaling networks, stress–arousal interfaces, and central autonomic modulation.

Target: Predominantly MC4R (with ancillary MC3R) in central nervous system circuits.
Mode: Agonism at melanocortin receptors → activation of G_s/cAMP pathways within hypothalamic and limbic structures → downstream effects on autonomic tone and arousal circuitry. Mechanistically, PT-141 operates independently of endothelial NO pathways, distinguishing it from peripherally focused vasoactive agents.
Selectivity: Designed for central activity with minimized peripheral endocrine spillover in research contexts.

Central arousal neurobiology • Hypothalamic–pituitary–autonomic integration • Reward and motivational circuitry mapping • Stress reactivity and autonomic modulation • Comparative studies versus NO-dependent vasodilatory mechanisms.

Revitalized Health peptides are produced under cGMP-aligned conditions using pharmaceutical-grade inputs. Each PT-141 lot is confirmed at ≥99% purity by HPLC with mass-spectrometric identity (LC-MS/MS). Lots are assessed for appearance, solubility, and microbial quality; endotoxin thresholds are monitored to research-grade specifications. Certificates of Analysis documenting identity, purity, and method parameters are available per batch.

Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor-binding fidelity.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic use. Supplied exclusively to qualified professionals conducting controlled scientific studies.

Identity: Bremelanotide (PT-141), a melanocortin receptor peptide agonist (primarily MC4R/MC3R; MC1R activity contributes to cutaneous effects).
Mode: Engages hypothalamic melanocortin pathways involved in sexual motivation/arousal independent of nitric-oxide mechanisms; CNS effects include modulation of reward/salience circuits and sympathetic outflow. Peripheral signals (e.g., MC1R) explain flushing and pigmentary changes in some users.
Analytics/QA: Identity & purity by HPLC/LC-MS; peptide content & counter-ion; sterility/endotoxin (parenteral); stability (accelerated/real-time). PD/readouts: validated sexual function scales, time-to-effect logs, HR/BP monitoring around dose, adverse-event/tolerability tracking. Cautions: avoid use in uncontrolled hypertension or cardiovascular instability; common AEs include nausea, flushing, headache; rare hyperpigmentation with repeated exposure. Marketing pages should avoid disease-treatment claims.